• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DBC1表达在人类癌症中的预后及临床病理价值：一项系统评价与Meta分析

Prognostic and clinicopathological value of dbc1 expression in human cancers: a systematic review and meta-analysis.

作者信息

Wang Haojia, Cheng Xinhong, Zhang Bruce Xianzhuo, Wang Yong, Gao Shuo, Ding Fanghui, Song Xiaojing, Li Dandan, Ni Haixu, Luo Yang, Li Xun

机构信息

The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.

Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China.

出版信息

Front Oncol. 2025 Jul 7;15:1584622. doi: 10.3389/fonc.2025.1584622. eCollection 2025.

DOI:10.3389/fonc.2025.1584622
PMID:40692869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12278428/
Abstract

BACKGROUND

DBC1 is a large nuclear protein that is thought to influence the development of several human cancers. However, further research has revealed that the relationship between DBC1 and the prognosis and pathological characteristics of cancer patients is controversial. The aim of this paper is to explore the significance of DBC1 in cancer through the method of meta-analysis.

METHODS

A systematic search of the PubMed, Web of Science, Embase, CNKI, and Wanfang databases was conducted, resulting in the identification of 25 studies encompassing 4014 patients. The Hazard Ratio (HR) and ratio ratios (RR) were combined using STATA 14.0 software, and 95% confidence intervals (CI) were obtained to assess the association of DBC1 with prognostic and pathologic characteristics of cancer patients.

RESULTS

Meta-analysis of the combined results demonstrated that patients with cancer who exhibited DBC1 overexpression exhibited shorter overall survival (OS) (n = 17, HR = 1.948, 95%CI: [1.280-2.964], P = 0.002, = 88.6) and recurrence-free survival (RFS) (n = 11, HR = 2.182, 95%CI: [1.430-3.330], P = 0.000, = 87.8) rates. In terms of pathological features, elevated DBC1 expression was indicative of poor TNM stage (n = 23, RR = 1.245, 95%CI: [1.012-1.531], P = 0.038, = 79.3), distant metastasis (n = 11, RR = 1.987, 95%CI: [1.021-3.866], P = 0.043, = 63.8), and histologic grade (n = 18, RR = 1.433, 95%CI: [1.115-1.843], P = 0.005, = 79.2).

CONCLUSION

DBC1 overexpression is associated with poor survival cycle and pathologic features in cancer patients, and it has the potential to be a predictive prognostic marker for cancer. However, more high-quality prospective studies are still needed to validate our conclusions.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/prospero/, identifier CRD42023426104.

摘要

背景

DBC1是一种大型核蛋白，被认为会影响多种人类癌症的发展。然而，进一步研究发现，DBC1与癌症患者的预后及病理特征之间的关系存在争议。本文旨在通过荟萃分析方法探讨DBC1在癌症中的意义。

方法

对PubMed、Web of Science、Embase、CNKI和万方数据库进行系统检索，共纳入25项研究，涉及4014例患者。使用STATA 14.0软件合并风险比（HR）和比值比（RR），并获得95%置信区间（CI），以评估DBC1与癌症患者预后和病理特征的相关性。

结果

综合结果的荟萃分析表明，DBC1过表达的癌症患者总生存期（OS）较短（n = 17，HR = 1.948，95%CI：[1.280 - 2.964]，P = 0.002，I² = 88.6），无复发生存期（RFS）也较短（n = 11，HR = 2.182，95%CI：[1.430 - 3.330]，P = 0.000，I² = 87.8）。在病理特征方面，DBC1表达升高表明TNM分期较差（n = 23，RR = 1.245，95%CI：[1.012 - 1.531]，P = 0.038，I² = 79.3）、远处转移（n = 11，RR = 1.987，95%CI：[1.021 - 3.866]，P = 0.043，I² = 63.8）和组织学分级较差（n = 18，RR = 1.433，95%CI：[1.115 - 1.843]，P = 0.005，I² = 79.2）。

结论

DBC1过表达与癌症患者的不良生存周期和病理特征相关，有可能成为癌症的预测性预后标志物。然而，仍需要更多高质量的前瞻性研究来验证我们的结论。

系统评价注册

https://www.crd.york.ac.uk/prospero/，标识符CRD42023426104。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/0284ce660009/fonc-15-1584622-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/0dcc378d9dba/fonc-15-1584622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/1173672ddd0e/fonc-15-1584622-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/61b4f301dbb3/fonc-15-1584622-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/37369ca4b739/fonc-15-1584622-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/695535ca8645/fonc-15-1584622-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/12b6e820beb7/fonc-15-1584622-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/cb3821a2ca8b/fonc-15-1584622-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/0284ce660009/fonc-15-1584622-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/0dcc378d9dba/fonc-15-1584622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/1173672ddd0e/fonc-15-1584622-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/61b4f301dbb3/fonc-15-1584622-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/37369ca4b739/fonc-15-1584622-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/695535ca8645/fonc-15-1584622-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/12b6e820beb7/fonc-15-1584622-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/cb3821a2ca8b/fonc-15-1584622-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a6/12278428/0284ce660009/fonc-15-1584622-g008.jpg

相似文献

1
Prognostic and clinicopathological value of dbc1 expression in human cancers: a systematic review and meta-analysis.DBC1表达在人类癌症中的预后及临床病理价值：一项系统评价与Meta分析
Front Oncol. 2025 Jul 7;15:1584622. doi: 10.3389/fonc.2025.1584622. eCollection 2025.
2
Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.通过 RT-PCR 检测非转移性结直肠癌循环肿瘤细胞的预后和临床病理意义：荟萃分析和系统评价。
BMC Cancer. 2017 Nov 7;17(1):725. doi: 10.1186/s12885-017-3704-8.
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
5
Adjuvant radiotherapy for stage I endometrial cancer.I期子宫内膜癌的辅助放疗
Cochrane Database Syst Rev. 2012 Mar 14(3):CD003916. doi: 10.1002/14651858.CD003916.pub3.
6
Adjuvant radiotherapy for stage I endometrial cancer.I期子宫内膜癌的辅助放疗
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD003916. doi: 10.1002/14651858.CD003916.pub4.
7
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.对早期预后不良或晚期霍奇金淋巴瘤患者，比较包括强化BEACOPP方案的一线化疗与包括ABVD方案的化疗。
Cochrane Database Syst Rev. 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3.
8
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.对局部晚期宫颈癌女性患者进行子宫切除术并辅以放疗或化疗或两者联合治疗。
Cochrane Database Syst Rev. 2015 Apr 7(4):CD010260. doi: 10.1002/14651858.CD010260.pub2.
9
Elevated platelet-to-lymphocyte ratio predicts poor clinical outcomes in non-muscle invasive bladder cancer: a systematic review and meta-analysis.血小板与淋巴细胞比值升高预示非肌层浸润性膀胱癌的临床预后不良：一项系统评价和荟萃分析
Front Immunol. 2025 May 13;16:1578069. doi: 10.3389/fimmu.2025.1578069. eCollection 2025.
10
Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation.性别作为肾移植后同种异体移植及患者相关预后的预测因素。
Cochrane Database Syst Rev. 2024 Dec 19;12(12):CD014966. doi: 10.1002/14651858.CD014966.pub2.

本文引用的文献

1
Mechanistic insights into the dual role of CCAR2/DBC1 in cancer.深入了解 CCAR2/DBC1 在癌症中的双重作用的机制见解。
Exp Mol Med. 2023 Aug;55(8):1691-1701. doi: 10.1038/s12276-023-01058-1. Epub 2023 Aug 1.
2
The sirtuin family in health and disease.长寿蛋白家族与健康和疾病。
Signal Transduct Target Ther. 2022 Dec 29;7(1):402. doi: 10.1038/s41392-022-01257-8.
3
Acetylation of nuclear receptors in health and disease: an update.核受体乙酰化在健康和疾病中的作用：最新进展。
FEBS J. 2024 Jan;291(2):217-236. doi: 10.1111/febs.16695. Epub 2022 Dec 19.
4
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.癌症中的突变型 p53：从分子机制到治疗调节。
Cell Death Dis. 2022 Nov 18;13(11):974. doi: 10.1038/s41419-022-05408-1.
5
Hypoxia-induced proteasomal degradation of DBC1 by SIAH2 in breast cancer progression.缺氧诱导 SIAH2 介导的 DBC1 蛋白酶体降解在乳腺癌进展中的作用。
Elife. 2022 Aug 1;11:e81247. doi: 10.7554/eLife.81247.
6
DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300.DBC1 是增强子表观遗传 writers KMT2D 和 p300 的关键正调控因子。
Nucleic Acids Res. 2022 Aug 12;50(14):7873-7888. doi: 10.1093/nar/gkac585.
7
Cancer treatment and survivorship statistics, 2022.2022 年癌症治疗和生存统计。
CA Cancer J Clin. 2022 Sep;72(5):409-436. doi: 10.3322/caac.21731. Epub 2022 Jun 23.
8
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
9
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明：系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.